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As a result of DNA damage, p53 induces the expression of several
downstream genes including p21/WAF1 (El-Deiry et al, 1994).
The p21 protein binds to and inhibits cyclin-dependent kinases
(Cdks) resulting in cell-cycle arrest during the G1 to S transition
(Harper et al, 1993). The expression of p21/WAF1 has been shown
to correlate inversely with a variety of cell proliferation markers
(El-Deiry et al, 1993; Doglioni et al, 1996; Mateo et al, 1997). In
addition, p21 immunoreactivity was recently observed to be
related to cell differentiation as well (El-Deiry et al, 1995).
Furthermore, the lack of p21 immunoreactivity has been related to
other prognostic factors and survival in breast (Wakasugi et al,
1997) and gastric cancers (Gomyo et al, 1997; Ogawa et al, 1997)
but no data on the prognostic significance of p21/WAF1 expres-
sion in epithelial ovarian cancer are available as yet.
In Finland 595 ovarian cancers were diagnosed in 1995 and the
mortality rate was 6.6/100 000 (Finnish Cancer Registry, 1997). In
Western countries the incidence rate of ovarian cancer is about 15
per 100 000 women (Boring et al, 1994; Engeland et al, 1995) and
in the United States it is estimated that 26 800 women will mani-
fest ovarian cancer, and of these there will be 14 200 deaths in
1997 (Parker et al, 1997). Previous studies have shown that the
p53 gene is mutated in 30–80% of the ovarian cancers and these
genetic changes closely correlate with the accumulation of mutant
p53 in tumour tissue (Marks et al, 1991; Kohler et al, 1993a;
Kohler et al, 1993b). p21/WAF1 protein expression has been
detected in the cells with wild-type p53, but not in those lacking
p53 protein activity (El-Deiry et al, 1994). Inferred from these
observations, dysregulation of p21/WAF1 could provide growth
advantage to tumour cells also in ovarian cancer. The p21/WAF1
gene is located on chromosome 6p21.2, and ovarian tumours
frequently show losses of heterozygosity in this region (Wan et al,
1994). Moreover, some recent data indicate that p53-independent
pathways may also lead to an increase in p21/WAF1 expression
(Jiang et al, 1994; Michieli et al, 1994). In epithelial ovarian
cancer, no correlation between p21/WAF1 expression and p53 or
Ki-67 has been demonstrated so far (Barboule et al, 1995, Werness
et al, 1997).
We used immunohistochemistry (IHC) to assess the expression
of p21/WAF1, p53 and the cell proliferation marker Ki-67 in a
cohort of 316 patients with epithelial ovarian cancer. In addition to
exploring the inter-relationships of these cell-cycle proteins, our
major aim was to analyse whether p21/WAF1 protein levels are
related to significant clinical data, histological parameters and
disease outcome of this group of malignancies.
MATERIALS AND METHODS
Clinical data
The material of the present study was selected from a consecutive
series of 445 women diagnosed and treated for ovarian malig-
nancy at Kuopio University Hospital and Jyväskylä Central
Hospital, Finland, between 1976 and 1992 (and subsequently
followed-up until September 1996), by excluding the nonepithelial
type of neoplasia from the present study. Patients who were given
any treatment before the primary operation were also excluded.
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Summary The role and prognostic value of the tumour suppressor p21/WAF1 expression in epithelial ovarian cancer has not yet been
defined. Therefore, the expression of p21/WAF1 was assessed immunohistochemically (IHC) in 316 epithelial ovarian malignancies in
relation to p53, cell proliferation and patient survival. p21/WAF1 expression was inversely correlated with p53 and cell proliferation. Low
p21/WAF1 expression was significantly associated with high grade of the tumour (P = 0.0005), advanced FIGO stage (P = 0.001) and primary
residual tumour (P = 0.0001). Low p21/WAF1 expression was a marker of poor overall survival (P = 0.012). Similarly, p53-positivity and high
cell proliferative activity were significant predictors of poor survival in univariate analyses. Moreover, the patients with p21–/p53+ tumours had
a poorer overall (P < 0.00005) and recurrence-free (P = 0.0005) survival in univariate analyses, and the p21/p53 expression independently
predicted tumour recurrence in Cox’s multivariate analysis. Our results suggest that p21/WAF1 expression is mostly p53-dependent in
epithelial ovarian cancer. High p21/WAF1 expression seems to function as a negative cell cycle regulator and as a marker of favourable
disease outcome in epithelial ovarian cancer. In addition, the patients with their tumour expressing no or low p21/WAF1 protein but positive
for p53 had a notably higher risk of recurrent disease, implicating that these patients might be more prone to treatment failures.
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Depending on the availability of representative tumour material,
316 valid immunostainings for p53 and Ki-67 and 305 for
p21/WAF1, respectively, could be completed in the present study.
All tumours were staged according to the International
Federation of Gynecology and Obstetrics standards (Cancer
Committee of the International Federation of Gynecology and
Obstetrics, 1989). Retrospective review of the patient files was
performed to obtain all pertinent data on the primary tumour, type
of surgery, adjuvant treatment, recurrence and survival. In case of
incomplete primary information, the patients were retrospectively
assigned a FIGO staging on the basis of these patient files. Patients
who died because of any postoperative complications were
excluded from the survival analyses. The pertinent clinicopatho-
logical data of the patients are summarized in Table 1.
Of the 316 patients, 121 underwent radical surgery (i.e. no
primary residual tumour), 230 received postoperative chemo-
therapy, nine received postoperative radiotherapy and 39 women
received both therapies. Second-look or other debulking operation
was performed on 29% of the patients. Disease recurrence was
observed in 76 patients (44%) and no recurrence in
95 patients (56%). The median follow-up time for all patients
(n = 316) was 29 months (range 1–237 months) and for patients
still alive (n = 78), 108 months (range 22–237 months).
Histology
The primary tumour samples were fixed in 10% formalin and
embedded in paraffin. From each sample, 5-mm thick sections
were stained with haematoxylin and eosin (HE). Histological
typing and grading were done according to the WHO classification
(Serov et al, 1973). All tumours were graded as either well, moder-
ately or poorly differentiated by one pathologist (KS). Borderline
tumours were excluded from the study. This microscopic re-evalu-
ation was performed in the most representative slides, equivalent
to the ones used for IHC analyses.
Immunohistochemistry
p21/WAF1 and p53 immunostaining
Sections were deparaffinized, rehydrated, washed for 2 ´ 5 min
with distilled water and for p21 analysis boiled in a microwave
oven in 0.01-M citrate buffer (pH = 6.0) for 5 ´ 5 min for antigen
retrieval. Endogenous peroxidase activity was blocked by 5%
hydrogen peroxide for 5 min, followed by washings for 2 ´ 3 min
with distilled water and 2 ´ 5 min with PBS (pH = 7.2). After
blocking the nonspecific staining with normal horse serum, the
tissue sections were incubated with the p21-specific mouse mono-
clonal antibody (NCL-WAF-1, Novocastra Laboratories Ltd, UK)
at a working dilution of 1:10, overnight at + 4 °C. Samples were
washed twice for 5 min with PBS and incubated for 30 min with
biotinylated secondary antibody (Vectastain ABC Elite Kit, Vector
Laboratories, CA, USA) in PBS. After two washings for 5 min in
PBS, the sections were incubated for 40 min in preformed avidin-
biotinylated peroxidase complex solution. Samples were washed
2 ´ 5 min with PBS, developed with diaminobenzidine tetra-
hydrochloride (DAB) substrate (Sigma, UK) for 5 min, slightly
counterstained with Mayer’s haematoxylin, dehydrated, cleared
and mounted with DePex (BDH Limited, Poole, UK).
The p53 protein was demonstrated using a similar IHC staining
protocol. We used a polyclonal CM1 (Novocastra Laboratories
Ltd, Newcastle upon Tyne, UK) at a working dilution of 1:1200
without antigen retrieval. In each batch, known p53- and p21-posi-
tive tumour samples were used as positive controls, and the same
biopsy processed without the primary antibody was used as a
negative control.
Ki-67 immunostaining
For Ki-67 detection, the monoclonal anti-Ki-67 antibody (MIB1,
Immunotech, France) was used and diluted at 1:50 in PBS. In
brief, 5-mm sections from the tumours were deparaffinized, rehy-
drated, and washed for 5 min with phosphate-buffered saline
(PBS). The sections were heated in a microwave oven for
5  ´ 5 min in 0.01-M citrate buffer (pH = 6.0). After microwave,
the slides were rinsed with Tris-buffered saline (pH = 7.4).
Endogenous peroxidase activity was blocked by 5% hydrogen
peroxide for 5 min, followed by a wash for 5 min with PBS.
Indirect ABC technique was used as described above. Tonsillar
tissue sections served as positive controls.
Table 1 Clinical data of the patients
Age (years)
Median 62
Range 18–85
Histological type
Epithelial
Serous 111 (35%)
Mucinous 36 (11%)
Endometrioid 84 (27%)
Clear cell 32 (10%)
Miscellaneousa 53 (17%)
Histological grade
1 48 (15%)
2 107 (34%)
3 161 (51%)
FIGO stage
I 86 (27%)
II 47 (15%)
III 150 (48%)
IV 33 (10%)
Primary residual tumour
No data 30 (10%)
None 121 (38%)
≤ 2 cm 53 (17%)
> 2 cm 112 (35%)
Adjuvant chemotherapy
Platinum-containing 167 (53%)
No platinum-containing 99  (32%)
None 47 (15%)
Chemotherapy response
No data 7  (2%)
CR 142 (45%)
PR 40 (13%)
SD 22 (7%)
PD 58 (18%)
Cause of death
Ovarian cancer 204 (64%)
Other cause 34  (11%)
Alive 78 (25%)
Total 316 (100%)
aIncludes 20 mixed epithelial, one Brenner, 32 unclassified epithelial. PR,
partial response; CR, complete response; SD, stable disease; PD,
progressing disease, no chemotherapy 47 (15%).1872 MA Anttila et al
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Scoring of the p21/WAF1 immunostaining
All slides were evaluated with a microscope (field diameter =
490 mm) by one observer (MA), who was unaware of the clinical
outcome of the patients. For p21, the positivity was assessed as the
percentage of positively-stained tumour cell nuclei in the entire
tumour area. For further analyses, p21/WAF1 immunoreactivity
was categorized into two groups: (1) low expression if < 10% of
the tumour cell nuclei were positive, and (2) high expression, if
³ 10% of the tumour cell nuclei were positive. The 10% cut-off
point was the 75th percentile of the p21/WAF1 expression.
Scoring of the p53 and Ki-67 immunostaining
The p53 and Ki-67 immunostaining was quantified using a digi-
tized image analysis system, CAS 200 (Cell Analysis System Inc.,
Elmhurst, IL, USA) by one observer (MA), who was unaware of
the clinical outcome of the patients. A quantitative ER/PR Package
(Cell Analysis System Inc, Version 2.0) for p53 and a software
package (Quantitative Proliferation Index) for Ki-67 utilizing two-
colour image analysis system to calculate the proportion of p53-
and Ki-67-positive area in relation to the total nuclear area was
used interactively. The p53- and Ki-67-positive tumour cell nuclei
Table 2 The correlation of p21/WAF1 expression with p53 and cell proliferation in epithelial ovarian cancer
Sample p21/WAF1 Expression (%) c2 df P
No. Low High
p53 expression 305 21.5 1 < 0.000005
Negative 224 63 37
Positive 81 90 10
Cell proliferation 303 10.3 1 0.001
Low 84 56 44
High 219 75 25
Table 3 The relationships between p21/WAF1 expression and clinicopathological factors in epithelial ovarian cancer
Factor Sample p21/WAF1 Expression (%) c2 df P
No. Low High
Histological type 305 42.8 4 < 0.000005
Serous 110 76 25
Mucinous 31 77 23
Endometrioid 81 73 27
Clear cell 31 19 81
Miscellaneous 52 81 19
Histological grade 305 12.1 1 0.00049
14 3 5 8 4 2
2 106 60 40
3 156 80 20
FIGO stage 305 10.4 1 0.001
I8 1 5 9 4 1
II 46 57 43
III 147 78 22
IV 31 77 23
Primary residual tumour 279 14.7 1 0.0001
None 118 60 40
≤ 2c m 5 1 6 3 3 7
> 2 cm 110 84 16
Chemotherapy response 255 4.2 3 0.24
CR 136 65 35
PR 40 80 20
SD 21 71 29
PD 58 74 26
Recurrence 162 1.3 1 0.26
No 91 60 40
Yes 71 69 31
End state 305 5.9 1 0.015
Dead 230 74 26
Alive 75 59 41p21/WAF1 in epithelial ovarian cancer 1873
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as a percentage were calculated on at least 10 randomly selected
fields using the ´ 400 magnification. For further correlation with
the clinicopathological data, the p53-immunostaining was classi-
fied as (1) positive, when over 10% nuclei stained positive and (2)
negative when less than 10% of the nuclei were positive (Kohler et
al, 1993a). The Ki-67 positivity was classified into two groups: (1)
low proliferation group when < 20% of the tumour cells were Ki-
67-positive and (2) high proliferation group when ³ 20% of the
tumour cells were positive (Garzetti et al, 1995).
Statistical analyses
The SPSS-Win 7.5 program package was used in a PC computer
for basic statistical calculations. First, the relationships (Spearman
correlations) between p21, p53 and Ki-67 expression levels were
analysed. Each parameter in the analysis was considered as a
continuous variable. The inter-relationships between the categor-
ical IHC variables and their association with clinicopathological
parameters were examined by contingency tables, which were
further analysed by c2-tests. Univariate survival analyses were
based on the Kaplan–Meier method (log-rank analysis) (Kaplan
and Meier, 1958). Multivariate survival analysis was done with the
SPSS-Cox programme package using the log likelihood ratio
significance test in forward-stepwise manner (Cox, 1972). Overall
survival was defined as the time interval between the date of
surgery and the date of death due to ovarian cancer. Recurrence-
free survival was defined by the time interval between the date of
surgery and the date of diagnosed recurrence. Probability values
less than 0.05 were regarded as significant. In Cox’s multivariate
analysis a removal limit of P < 0.10 was used as an additional
criteria.
RESULTS
p21/WAF1 immunostaining
A total of 305 primary ovarian tumours were evaluable for
p21/WAF1 immunostaining. p21/WAF1 staining was confined to
the tumour cell nuclei (Figure 1A). The median percentage of
p21/WAF1-positive tumour cell nuclei was 3.0% (range 0–90%).
Of the 305 cases, 26% (n = 82) were entirely negative for
p21/WAF1, whereas 30% of the tumours showed high expression
A
B
Figure 2 Endometrioid carcinoma of the ovary showing (A) a few weakly
p21/WAF1-positive nuclei (arrow). (B) Note the strong positivity for p53
protein. Bar = 50 mm
A
B
Figure 1 Clear cell carcinoma of the ovary showing (A) a high expression
of p21/WAF1 protein but (B) negative for p53 protein. Bar = 30 mm1874 MA Anttila et al
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of p21/WAF1, the staining being diffuse in 73% of these positive
tumours.
p53 and Ki-67 immunostaining
p53 staining was confined to tumour cell nuclei (Figure 2B), and
only a few cases with cytoplasmic staining were observed. Any
degree of nuclear p53 immunopositivity was observed in 30% of
the primary tumours. According to the 10% cut-off point, 26%
(n = 83) of the tumours were positive for p53 protein. Similarly,
the Ki-67 staining was also observed in tumour cell nuclei. The
median percentage of Ki-67-positive tumour cell nuclei was 29%
(range 0–78%). Accordingly, 71% of the primary tumours were
considered to be highly proliferative.
Table 4 Univariate overall and recurrence-free survival analysis of the patients
Factor Surviving Recurrence-free
at 5 years at 5 years
N % Pa N % Pa
Age at diagnosis (years) 306 0.0005 166 0.15
< 50 65 55 40 68
50–65 130 37 74 50
> 65 111 25 52 48
Histological grade 306 0.0002 166 0.15
1 4 85 4 3 16 7
2 106 48 63 62
3 152 23 72 43
Histological type 306 0.096 166 0.0098
Serous 110 28 52 39
Mucinous 36 54 28 61
Endometrioid 82 36 41 67
Clear cell 31 51 22 62
Miscellaneous 47 35 23 53
Primary residual tumour 281 < 0.00005 158 < 0.00005
None 123 70 105 70
≤ 2 cm 53 20 30 38
> 2 cm 105 8 23 16
p21/WAF1 expression 295 0.012 157 0.23
Low 203 31 99 50
High 92 47 58 64
p53 expression 306 < 0.00005 166 0.0006
Negative 226 44 137 60
Positive 80 17 29 28
p21/p53 expression 295 < 0.00005 157 0.0004
p21–/p53+ 70 15 24 21
p21+/p53– 84 47 54 62
p21+/p53+ 8 38 4 75
p21–/p53– 133 40 75 59
Cell proliferation 304 <0.00005 166 0.002
Low 88 54 60 70
High 216 30 106 46
aLog-rank analysis.
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Figure 3 Kaplan–Meier overall survival analysis of the patients with
tumours expressing high or low p21/WAF1 protein
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Figure 4 Kaplan–Meier overall survival analysis of the patients with
different combinations of p21/WAF1 and p53 expressionp21/WAF1 in epithelial ovarian cancer 1875
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Relation of p21/WAF1 expression to p53 and cell
proliferation
An inverse correlation was observed between p21/WAF1 and p53
expression (Spearman, r = – 0.24, P < 0.0005) (see Figures 1 and 2)
and Ki-67 expression (Spearman, r = – 0.20, P < 0.0005) as shown
in the contingency tables (Table 2). Positive p53 expression was
directly associated with high cell proliferation (c2, P = 0.0001);
88% of the p53-positive tumours were highly proliferative.
Relation of p21/WAF1 expression to the
clinicopathological data
The low expression of p21/WAF1 protein was significantly associ-
ated with the high grade, advanced stage, serous and miscella-
neous epithelial type of tumour (Table 3). Clear cell tumours
showed high expression of p21/WAF1 protein. In those patients
with the primary residual tumour > 2 cm, 84% of the tumours
expressed low p21/WAF1 protein (Table 3). Importantly, 79% of
the patients who eventually died of their disease during the follow-
up, had low p21/WAF1 expression in their tumours.
Relation of p53 expression and cell proliferation to the
clinicopathological data
The p53-positivity was significantly associated with high grade
of the tumour (c2,  P = 0.0004), with advanced FIGO stage
(P = 0.0001), presence of residual tumour (P = 0.00001), serous
histological type (P = 0.005) and recurrence of the disease
(P = 0.007). A significant correlation was observed between
the fatal disease outcome and p53-positivity (P = 0.00002). In
the complete chemotherapy response group, there were more
p53-negative (83%) than p53-positive tumours (18%) (P = 0.001).
Table 5 Results of Cox’s multivariate analysis for overall and recurrence-free survival
Category Beta (SE) Relative risk P-value
(95% CI)
Overall survival
FIGO stage 0.0006
I
II 0.51 (0.35) 1.66 (0.84–3.28) 0.14
III 0.88 (0.37) 2.42 (1.17–5.01) 0.018
IV 1.63 (0.42) 5.12 (2.23–11.74) 0.0001
Age at diagnosis (years) 0.02
<50
50–65 0.44 (0.24) 1.55 (0.97–2.46) 0.067
>65 0.67 (0.24) 1.95 (1.22–3.13) 0.0055
Primary residual tumour < 0.00005
None
≤ 2 cm 1.17 (0.31) 3.21 (1.73–5.94) 0.0002
> 2 cm 1.54 (0.31) 4.65 (2.52–8.59) < 0.00005
Adjuvant chemotherapy 0.019
Platinum-containing
Non-platinum 0.35 (0.18) 1.42 (1.00–2.02) 0.047
None 0.78 (0.31) 2.19 (1.18–4.06) 0.013
Recurrence-free survival
Histological type 0.038
Serous
Mucinous – 0.73 (0.46) 0.48 (0.20–1.18) 0.11
Endometrioid – 0.86 (0.37) 0.42 (0.21–0.87) 0.019
Clear cell – 0.42 (0.40) 0.66 (0.30–1.46) 0.31
Miscellaneous – 0.93 (0.38) 0.39 (0.19–0.84) 0.015
Primary residual tumour < 0.00005
None
≤ 2 cm 0.89 (0.32) 2.43 (1.31–4.50) 0.0049
> 2 cm 1.56 (0.32) 4.78 (2.54–8.98) < 0.00005
p53 expression
Negative
Positive 0.75 (0.30) 2.11 (1.17–3.81) 0.013
p21/p53 expression 0.0072
p21–/p53+
p21+/p53– – 1.06 (0.36) 0.34 (0.17–0.70) 0.0037
p21+/p53+ –a
p21–/p53– – 1.08 (0.33) 0.34 (0.17–0.65) 0.0012
aNot stable due to few cases.High proliferative activity (determined by Ki-67 expression)
was significantly related to the high grade (c2, P = 0.001) and to
the advanced stage (P < 0.001) of the tumour, as well as disease
recurrence (P = 0.013) and death (P < 0.001).
Survival
Clinicopathological factors and survival
At the end of the follow-up 238 (75%) patients were dead, 204
(86%) due to their ovarian cancer. The median overall survival of
the patients (n = 316) was 33 months (95% CI, 26–40) and the 5-year
overall survival rate was 37%. In univariate survival analysis, the high
grade disease, advanced stage, older age at diagnosis, primary residual
tumour > 2 cm and platinum-containing adjuvant chemotherapy
(P = 0.046) were significant predictors of poor overall survival (Table
4). In univariate recurrence-free analysis, only the serous histological
type and the primary residual tumour > 2 cm were associated signifi-
cantly with the recurrent disease (Table 4).
p21/WAF1 expression and survival
The low p21/WAF1 expression was a significant predictor of poor
overall survival (P = 0.012) in the univariate analysis (Table 4,
Figure 3). The p21/WAF1 expression had no significant associa-
tion with the overall survival in the different subgroups of histo-
logical grade, FIGO stage, primary residual tumour, cell
proliferation or p53 expression. In the serous tumours, the high
p21/WAF1 expression predicted better 5-year survival (44% vs
22%) (P = 0.01). In the older age group (> 65 years), the low
p21/WAF1 expression predicted poor overall survival (P = 0.04).
In the recurrence-free survival analysis, p21/WAF1 expression had
no predictive value (Table 4).
p53 expression, proliferative activity and survival
The p53-positivity and high proliferative activity were strongly
associated with both the overall and recurrence-free survival
(Table 4). Patients with p53-positive tumours had only 17% 5-year
overall survival as, compared with 44% survival of the patients
with p53-negative tumours (P < 0.00005). Similarly, highly pro-
liferative tumours had 30% 5-year overall survival compared with
that (54%) of the tumours with low proliferative activity. By
combining the results of p21/WAF1 and p53 expression, the
patients with p21–/p53+ tumours had a poorer prognosis in the
univariate overall (P < 0.00005) (Fig. 4) and recurrence-free
(P = 0.0005) survival analyses compared with patients who had
other combinations of these two proteins in their tumours (Table
4). This was independent of the dichotomized histological grade
(grade 1–2 vs grade 3) but not of the FIGO stage, although the
prognostic value of p21–/p53+ expression reached a borderline
statistical significance in patients with FIGO stages III–IV
(P = 0.05). High cell proliferation was also a significant predictor
of poor overall survival in patients with both a low (P = 0.007) and
a high (P = 0.03) p21/WAF1 expression.
Multivariate survival analysis
The complete data for a multivariate overall analysis was available
from 265 patients. The histological grade and type, tumour stage,
primary residual tumour, adjuvant chemotherapy, age at diagnosis,
p21/WAF1 and p53 expression and tumour proliferation were
entered into Cox’s analysis. The FIGO stage, age at diagnosis,
primary residual tumour and adjuvant chemotherapy proved to be
significant predictors of the overall survival (Table 5). p53 expres-
sion, primary residual tumour and the histological type were
significant prognostic factors of recurrence-free survival (n = 148)
(Table 5). When the different combinations of p21/WAF1 and p53
expression replaced the p53 expression in the Cox’s analysis, they
retained independent statistical significance in the multivariate
recurrence-free analysis. Patients with p21+/p53– tumours had a
significantly lower risk for recurrent disease than patients who had
p21–/p53+ tumours (Table 5).
DISCUSSION
The p21/WAF1 gene is induced by any DNA-damaging agents
that trigger G1 arrest in cells with the wild-type p53 but not in
mutant p53-containing cells (El-Deiry et al, 1994). On the other
hand, studies using fibroblasts from p53 knock-out mice (Michieli
et al, 1994), breast carcinoma cells (Sheikh et al, 1994), human
leukaemia cells (Zhang et al, 1995) and ovarian cancer cells
(Elbendary et al, 1994) have shown that p53-independent path-
ways for p21/WAF1 induction exist as well. Due to the paucity of
data on the p21/WAF1 expression and its relation to p53, tumour
proliferation and patient survival in epithelial ovarian cancer, we
studied the present cohort of these ovarian neoplasms by IHC.
In the present series, p21/WAF1 expression was entirely absent
in 26% of the tumours. Any degree of p21/WAF1 positivity was
observed in 74% of the tumours, and intense positive signals in
30% of the cases. These figures are consistent with those reported
in a few previous studies, where p21/WAF1 expression was
detected in 7–75% of the ovarian tumours (Barboule et al, 1995;
Auer et al, 1996; Lukas et al, 1997; Werness et al 1997).
Shigemasa et al (1997) studied the p21/WAF1 mRNA expression
in 13 ovarian tumours and they found p53 mutation in 69% of
tumours underexpressing p21 mRNA. We found a statistically
significant inverse correlation between p21/WAF1 expression and
p53, which is in accordance with the data of Elbendary et al (1996)
in epithelial ovarian cancer cells, as well as with the observations
in breast cancer (Bukholm et al, 1997). Previous studies on gynae-
cological malignancies have shown either no correlation between
p21/WAF1 expression and p53, e.g. in ovarian (Werness et al.,
1997) and endometrial cancer (Backe et al, 1997; Ito et al, 1997),
or p53-independent expression of p21/WAF1 in cervival cancer
(Werness et al, 1997). Our results suggest, that p21/WAF1 expres-
sion is regulated p53-dependently in the vast majority of epithelial
ovarian cancers. It can also be assumed, that IHC detection of p53
accumulation is related to p53 mutation or to stabilized p53 after
functional inactivation by nonmutational events (Harada et al,
1997). However, the relationship between p21/WAF1 expression
and p53 is highly complex and seems to be tumour type-specific as
well.
p21/WAF1 negatively regulates cell proliferation by inhibiting
Cdks in some normal tissues (El-Deiry et al, 1995) and tumour
cells (El-Deiry et al, 1993). The present demonstration of an
inverse correlation between p21/WAF1 expression and a prolifera-
tion marker Ki-67 is in alignment with this notion (El-Deiry et al,
1993, 1995). Similarly, an inverse correlation between p21/WAF1
expression and Ki-67 was documented in endometrial cancer
(Palazzo et al, 1997). On the other hand, earlier studies with
ovarian (Barboule et al, 1995; Werness et al, 1997), endometrial
(Backe et al, 1997) and breast cancers (Diab et al, 1997) have
found no correlation between p21/WAF1 expression and tumour
1876 MA Anttila et al
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number of cases studied. It may well be that larger series of
tumours like the one of our present study are needed to demon-
strate the growth-inhibitory effects of p21/WAF1. It sounds
feasible that the blocking of cell proliferation by p21/WAF1 may
permit cell differentiation and senescence, as shown in several
human tissues, e.g. in lung carcinomas p21/WAF1 overexpression
is related to histological differentiation (Marchetti et al, 1996).
The low p21/WAF1 expression was significantly associated
with high grade of the tumour, advanced FIGO stage and serous or
miscellaneous epithelial histological type. Accordingly, 53% of
the serous and 87% of the miscellaneous epithelial tumours were
poorly differentiated and the low expression of p21/WAF1 in these
tumours indicates the relation of p21/WAF1 to tumour differentia-
tion (El-Deiry et al, 1995; Doglioni et al, 1996). In concordance of
the study of Werness et al (1997), we noticed a higher p21/WAF1
expression in clear cell tumours. There was a tendency for higher
p21/WAF1 expression in the group with complete chemotherapy
response but it did not reach statistical significance. However,
these findings suggest that tumours with p21/WAF1 expression
may have higher sensitivity to adjuvant chemotherapy. This is
supported by the data of Kondo et al (1996), who studied glioma
cells and noticed that p21/WAF1 did not induce apoptosis but
conferred the susceptibility to cisplatin.
No previous studies are available on the prognostic significance
of p21/WAF1 expression in epithelial ovarian malignancies. In the
present study, the lower p21/WAF1 expression was a significant
predictor of poorer overall survival in the univariate survival
analysis (47% vs 31% of 5-year survival rate, P = 0.012) but not of
the recurrence-free survival in either univariate or multivariate
survival analyses. This prognostic significance of p21/WAF1
expression has been reported in some neoplasias (Gomyo et al,
1997; Ito et al, 1997; Jiang et al, 1997; Ogawa et al, 1997;
Wagasuki et al, 1997), whereas other authors have failed to estab-
lish any such prognostic value (Ito et al, 1996; Backe et al, 1997;
Diab et al, 1997). The mechanisms by which the expression of
p21/WAF1 is associated with better prognosis is not known in any
detail as yet. p21/WAF1 may mediate growth arrest by inhibiting
further DNA synthesis, thus allowing the cells to continue their
differentiation. That is substantiated by our present observation of
an inverse correlation between p21/WAF1 and Ki-67, and the
significant association between the p21/WAF1 upregulation and
tumour differentiation (P = 0.00049). Furthermore, the p21/WAF1
expression seems to be related to the FIGO stage of the tumour, in
that the lower p21/WAF expression is confined to advanced stage
(P = 0.001). The same was observed in the study of Ogawa et al
(1997) in gastric cancer; patients with p21/WAF1-negative
tumours usually had a metastatic disease. The loss of independent
predictive value of p21/WAF in the multivariate survival analyses
may be explained by its p53-dependency. Thus, p53 expression
seems to be a stronger independent prognostic marker of survival
than p21/WAF1, masking the effect of the latter in the multivariate
analysis.
Both p53 expression and tumour cell proliferative activity were
of prognostic significance in the univariate overall and recurrence-
free survival analyses in this study. p53 expression had also inde-
pendent value in the multivariate recurrence-free analysis. Similar
data have been observed in other studies, where p53-positivity has
significantly predicted a poor survival (Henriksen et al, 1994;
Klemi et al, 1995; van der Zee et al, 1995; Herod et al, 1996).
However, contradictory results have been reported as well (Marks
et al, 1991; Kohler et al, 1993a; Levesque et al, 1995). The
observed prognostic significance of Ki-67 in the present study is
consonant with the data of Garzetti et al (1995). To assess further
the prognostic power of p53 and p21/WAF1, we combined the
p21/WAF1 expression to that of p53. Indeed, p21–/p53+ tumours
had a significantly lower survival than p21+/p53– tumours. This
observation retained its significance independently of the
dichotomized histological grade of the tumour. In the multivariate
recurrence-free analysis, combining the p21/WAF1 expression to
p53 even increased the power of p53 to predict the recurrent
disease. This implicates that the p21–/p53+ ovarian epithelial
neoplasia might be more prone to treatment failures.
In summary, p21/WAF1 expression seems to be p53-dependent
in epithelial ovarian cancer. p21/WAF1 expression also negatively
regulates cell proliferation and probably regulates cell differentia-
tion as well. In addition, the low p21/WAF1 expression was an
unfavourable prognostic sign in the univariate survival analysis,
although it lost its significance in the multivariate analysis.
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